Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2007 4
2008 14
2009 40
2010 69
2011 87
2012 103
2013 95
2014 54
2015 41
2016 46
2017 56
2018 59
2019 51
2020 72
2021 49
2022 43
2023 31
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

805 results

Results by year

Filters applied: . Clear all
Page 1
Clopidogrel Pharmacogenetics.
Pereira NL, Rihal CS, So DYF, Rosenberg Y, Lennon RJ, Mathew V, Goodman SG, Weinshilboum RM, Wang L, Baudhuin LM, Lerman A, Hasan A, Iturriaga E, Fu YP, Geller N, Bailey K, Farkouh ME. Pereira NL, et al. Circ Cardiovasc Interv. 2019 Apr;12(4):e007811. doi: 10.1161/CIRCINTERVENTIONS.119.007811. Circ Cardiovasc Interv. 2019. PMID: 30998396 Free PMC article. Review.
Common genetic variation in CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) *2 and *3 alleles leads to a loss of functional protein, and carriers of these loss-of-function alleles when treated with clopidogrel have significantly reduced clopidogrel …
Common genetic variation in CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) *2 and *3 alleles leads to a loss of functional …
Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA.
Wang Y, Meng X, Wang A, Xie X, Pan Y, Johnston SC, Li H, Bath PM, Dong Q, Xu A, Jing J, Lin J, Niu S, Wang Y, Zhao X, Li Z, Jiang Y, Li W, Liu L, Xu J, Chang L, Wang L, Zhuang X, Zhao J, Feng Y, Man H, Li G, Wang B; CHANCE-2 Investigators. Wang Y, et al. N Engl J Med. 2021 Dec 30;385(27):2520-2530. doi: 10.1056/NEJMoa2111749. Epub 2021 Oct 28. N Engl J Med. 2021. PMID: 34708996 Clinical Trial.
BACKGROUND: Comparisons between ticagrelor and clopidogrel for the secondary prevention of stroke in CYP2C19 loss-of-function carriers have not been extensively performed. ...(Funded by the Ministry of Science and Technology of the People's Republic of China and oth …
BACKGROUND: Comparisons between ticagrelor and clopidogrel for the secondary prevention of stroke in CYP2C19 loss-of-function carrier …
Association with CYP2C19 polymorphisms and Clopidogrel in treatment of elderly stroke patients.
Li C, Jia W, Li J, Li F, Ma J, Zhou L. Li C, et al. BMC Neurol. 2021 Mar 9;21(1):104. doi: 10.1186/s12883-021-02127-6. BMC Neurol. 2021. PMID: 33685396 Free PMC article.
BACKGROUND: Clopidogrel is an antiplatelet drug used in the treatment of ischemic stroke. Safety and efficacy of clopidogrel has been confirmed in CAPRIE, PRoFESS trials. However, these studies focused on patients aged less than 75 years. ...
BACKGROUND: Clopidogrel is an antiplatelet drug used in the treatment of ischemic stroke. Safety and efficacy of clopidogrel h …
Time Course for Benefit and Risk With Ticagrelor and Aspirin in Individuals With Acute Ischemic Stroke or Transient Ischemic Attack Who Carry CYP2C19 Loss-of-Function Alleles: A Secondary Analysis of the CHANCE-2 Randomized Clinical Trial.
Pan Y, Meng X, Jin A, Johnston SC, Li H, Bath PM, Xie X, Jing J, Lin J, Wang Y, Zhao X, Li Z, Jiang Y, Liu L, Yang H, Cheng J, Wang Z, Wang Y. Pan Y, et al. JAMA Neurol. 2022 Aug 1;79(8):739-745. doi: 10.1001/jamaneurol.2022.1457. JAMA Neurol. 2022. PMID: 35727586 Free PMC article. Clinical Trial.
INTERVENTIONS: Ticagrelor (180 mg on day 1 followed by 90 mg twice daily on days 2-90) or clopidogrel (300 mg on day 1 followed by 75 mg daily on days 2-90). ...RESULTS: A total of 6412 patients were included (3205 in the ticagrelor and aspirin group and 3207 in the clo …
INTERVENTIONS: Ticagrelor (180 mg on day 1 followed by 90 mg twice daily on days 2-90) or clopidogrel (300 mg on day 1 followed by 75 …
Response to clopidogrel and of the cytochrome CYP2C19 gene polymorphism.
Charfi R, Mzoughi K, Boughalleb M, Hosni H, Kouidhi S, Sfar I, Hammami N, Zaïri I, Limam M, Zedini C, Mrabet A, Klouz A, Gorgi Y, Kharrat M, Baccar H, Trabelsi S. Charfi R, et al. Tunis Med. 2018 Mar;96(3):209-218. Tunis Med. 2018. PMID: 30325490
INTRODUCTION: Clopidogrel (clopi) is a prodrug widely prescribed in the management of coronary artery disease and requires the intervention of hepatic cytochrome P450 2C19 (CYP2C19) for its activation. ...
INTRODUCTION: Clopidogrel (clopi) is a prodrug widely prescribed in the management of coronary artery disease and requires the interv …
Impacts of CYP2C19 Polymorphism and Clopidogrel Dosing on in-Stent Restenosis: A Retrospective Cohort Study in Chinese Patients.
Zhang M, Wang J, Zhang Y, Zhang P, Jia Z, Ren M, Jia X, Ma L, Gao M, Hou Y. Zhang M, et al. Drug Des Devel Ther. 2020 Feb 19;14:669-676. doi: 10.2147/DDDT.S242167. eCollection 2020. Drug Des Devel Ther. 2020. PMID: 32109992 Free PMC article.
METHODS: Totally, 111 patients were included, who underwent percutaneous coronary intervention (PCI) with drug-eluting stent. Patients received clopidogrel treatment after the intervention on the background treatment with aspirin, based on the genotypes: 75 mg clopidogr …
METHODS: Totally, 111 patients were included, who underwent percutaneous coronary intervention (PCI) with drug-eluting stent. Patients recei …
Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.
Pereira NL, Farkouh ME, So D, Lennon R, Geller N, Mathew V, Bell M, Bae JH, Jeong MH, Chavez I, Gordon P, Abbott JD, Cagin C, Baudhuin L, Fu YP, Goodman SG, Hasan A, Iturriaga E, Lerman A, Sidhu M, Tanguay JF, Wang L, Weinshilboum R, Welsh R, Rosenberg Y, Bailey K, Rihal C. Pereira NL, et al. JAMA. 2020 Aug 25;324(8):761-771. doi: 10.1001/jama.2020.12443. JAMA. 2020. PMID: 32840598 Free PMC article. Clinical Trial.
IMPORTANCE: After percutaneous coronary intervention (PCI), patients with CYP2C19*2 or *3 loss-of-function (LOF) variants treated with clopidogrel have increased risk of ischemic events. Whether genotype-guided selection of oral P2Y12 inhibitor therapy improves ischemic ou …
IMPORTANCE: After percutaneous coronary intervention (PCI), patients with CYP2C19*2 or *3 loss-of-function (LOF) variants treated with cl …
CYP2C19 polymorphisms and clopidogrel efficacy in the secondary prevention of ischemic stroke: a retrospective observational study.
Lin J, Mo Y, Cai D, Mao D, Fu H, Wei D. Lin J, et al. Ann Palliat Med. 2021 Dec;10(12):12171-12180. doi: 10.21037/apm-21-2905. Ann Palliat Med. 2021. PMID: 35016407 Free article.
BACKGROUND: The relationship between cytochrome P450 2C19 (CYP2C19) polymorphisms and clopidogrel efficacy in patients with percutaneous coronary intervention (PCI) has been widely studied. However, the relationship between CYP2C19 polymorphisms and the response to clop …
BACKGROUND: The relationship between cytochrome P450 2C19 (CYP2C19) polymorphisms and clopidogrel efficacy in patients with percutane …
Genetic considerations.
Price MJ. Price MJ. Adv Cardiol. 2012;47:100-13. doi: 10.1159/000338043. Epub 2012 Aug 9. Adv Cardiol. 2012. PMID: 22906906 Review.
Candidate gene and genome-wide association studies have found that common genetic polymorphisms of the cytochrome P450 (CYP) 2C19 isoenzyme that result in a loss of functional activity are associated with less exposure of clopidogrel active metabolite and a diminished anti …
Candidate gene and genome-wide association studies have found that common genetic polymorphisms of the cytochrome P450 (CYP) 2C19 isoenzyme …
Efficacy of clopidogrel for stroke depends on CYP2C19 genotype and risk profile.
Xu J, Wang A, Wangqin R, Mo J, Chen Z, Dai L, Meng X, Zhao X, Wang Y, Li H, Chen W, Xian Y, Wang Y; CHANCE investigators. Xu J, et al. Ann Neurol. 2019 Sep;86(3):419-426. doi: 10.1002/ana.25535. Epub 2019 Jul 18. Ann Neurol. 2019. PMID: 31237713 Clinical Trial.
OBJECTIVE: Dual antiplatelet therapy (DAT) with clopidogrel plus aspirin has been suggested by American Heart Association/American Stroke Association guidelines for minor stroke (MS) and transient ischemic attack (TIA) patients. ...No significant difference for stroke recu …
OBJECTIVE: Dual antiplatelet therapy (DAT) with clopidogrel plus aspirin has been suggested by American Heart Association/American St …
805 results